Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating cardiometabolic diseases driven by obesity, today announced that Jayson Dallas, M.D., chief executive officer, will provide a corporate update during a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
The corporate presentation will highlight Rivus‘ new class of investigational therapies, called Controlled Metabolic Accelerators (CMAs), and will include updates on the clinical development of its lead program, HU6, and preclinical pipeline progress. HU6 is a once-daily, oral investigational medicine that promotes sustained body fat loss while preserving muscle mass by increasing resting metabolic rate in a controlled manner. The company has completed the active six-month dosing phase of M-ACCEL, a Phase 2 study in 220 patients with metabolic dysfunction associated steatohepatitis (MASH), with topline data expected in the second quarter of 2025. M-ACCEL will be the third Phase 2 study of HU6 to be completed.
